Eupraxia Pharmaceuticals (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals has successfully raised C$44.5 million through a non-brokered private placement of preferred shares to support its clinical trials and other corporate initiatives. Additionally, the company strengthened its board with the appointment of Joseph Freedman, a seasoned private equity investor.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
